CRISPR Gene Therapy Cures Sickle Cell Disease
Recent breakthroughs in medical science have brought the promise of a permanent cure for sickle cell disease into reality. CRISPR-Cas9 gene editing technology, specifically the therapy known as Casgevy (exagamglogene autotemcel), has received regulatory approval in several major markets, including the United States and the United Kingdom. This guide outlines the conceptual process of how this groundbreaking treatment works, offering a step-by-step look at the journey from diagnosis to potential cure. While this is not a DIY medical procedure, understanding the mechanism empowers patients and families to navigate their healthcare decisions with confidence.
Step 1: Consultation and Eligibility Screening
The journey begins with a comprehensive evaluation by a hematologist specializing in sickle cell disease. Not every patient is an immediate candidate. Doctors assess the severity of symptoms, prior complications, and overall health status. Genetic testing confirms the specific mutation responsible for the sickling of red blood cells. During this phase, patients discuss the risks, benefits, and the intensive nature of the upcoming treatment with their medical team.
If you want to dig deeper, check out our guide on 10 Proven Business Growth Strategies to Boost Your Revenue i.
Step 2: Stem Cell Collection
Once approved, the first medical step is apheresis. This procedure collects hematopoietic stem cells (HSCs) from the patient’s bone marrow or peripheral blood. These are the “master cells” capable of developing into all types of blood cells. The collected stem cells are then sent to a specialized laboratory for gene editing. It is crucial for patients to stay hydrated and maintain good nutrition during this collection period to ensure a sufficient yield of healthy stem cells.
Step 3: Gene Editing with CRISPR
In the laboratory, scientists use the CRISPR-Cas9 system to edit the patient’s stem cells. The goal is not to fix the sickle cell gene directly but to reactivate the production of fetal hemoglobin. Fetal hemoglobin is naturally produced before birth and prevents red blood cells from sickling. The CRISPR tool acts
Leave a Reply